Company Overview
Spruce Biosciences, Inc. operates as a biopharmaceutical entity dedicated to the development and commercialization of novel therapies specifically designed for neurological disorders. The company focuses its resources on TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase which functions as an enzyme replacement therapy for patients. This business model places Spruce Biosciences within the Healthcare sector, specifically the Biotechnology industry, where the primary objective is the creation of high-cost, high-potential medical treatments rather than immediate consumer goods generation. The company currently maintains a market capitalization of $86.49M and employs a workforce of 8 individuals, indicating a highly specialized and lean operational structure typical of early-stage biotech firms. These financial figures suggest that the company exists in a phase where capital allocation is directed almost exclusively toward research, development, and regulatory approval processes rather than mass-scale commercial distribution or profit generation. The valuation of $86.49M reflects the market's assessment of the potential value of its pipeline assets, while the small employee count underscores the capital-intensive nature of the industry where significant value creation relies on scientific breakthroughs rather than headcount expansion.
Financial Health
The company reports revenue of N/A for the trailing twelve months, resulting in a net income of $-38,966,000 and an EBITDA of $-28,592,000. The absence of reported revenue combined with substantial net losses reveals a cost structure heavily weighted toward research and development expenditures, clinical trial costs, and general administrative overhead necessary to advance novel therapies. Free cash flow stands at $-16,669,375, indicating that the company is consuming cash reserves to fund its operations and asset development rather than generating surplus liquidity from its current activities. All three margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial profitability or that reported revenues are insufficient to cover direct costs and operating expenses in a way that generates positive margin percentages. Despite the losses, the balance sheet holds $48.91M in cash against a relatively minor debt obligation of $736,000, and the debt-to-equity ratio of 1.73 suggests a leveraged position relative to equity but one supported by significant cash liquidity. The current ratio of 5.17 demonstrates strong short-term liquidity, as the company possesses significantly more current assets than current liabilities, providing ample room to meet obligations without immediate refinancing needs. Return on Equity is -109.2% and Return on Assets is -36.4%, metrics that reveal that management is currently generating negative returns on the capital invested, a common characteristic for biotechnology firms in the pre-revenue stage where equity value is sustained by future potential rather than historical performance.
Valuation Assessment
The trailing P/E ratio is N/A while the forward P/E is -11.28, implying that the market is pricing the stock based on expected future earnings recovery or current cash flow dynamics rather than historical profitability. The price-to-book ratio stands at 2.03, indicating that the market values the company at a premium of 103% over its net book value, which reflects the high valuation placed on its intellectual property and pipeline assets despite current losses. The price-to-sales ratio is N/A and the EV/EBITDA is -1.34, suggesting that traditional earnings-based valuation multiples are inapplicable due to negative earnings, and the enterprise value metric highlights the negative earnings power relative to the company's total capital structure. The stock's 52-week high is $1951.88 and the 52-week low is $7.00, creating a volatility range where the current trading price sits significantly below the historical high, reflecting recent market correction or lack of recent trading volume near the upper bound. The beta value of 3.82 indicates that the stock price is highly volatile and moves with approximately 3.8 times the magnitude of the broader market, exposing investors to substantial price swings that exceed standard market risk levels.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, meaning that traditional growth rate metrics cannot be calculated to compare earnings expansion against revenue expansion due to the lack of historical revenue data. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which indicates that the company retains all available resources to reinvest into research, development, and clinical trials rather than distributing income to shareholders. This reinvestment strategy is standard for biotechnology firms in the development phase, where capital retention is prioritized to achieve regulatory approval and commercial launch of therapies like TA-ERT. The overall growth and income profile is characterized by a complete reliance on capital markets for funding and a lack of current income generation, with the company's value proposition hinging entirely on the successful commercialization of its neurological disorder therapies in the future.